A Systematic Review of the Design, Method of Implantation and Early Clinical Outcomes of Transcatheter Tricuspid Prostheses

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39076710

Authors

Faizus Sazzad

Yinling Zhu

Hwa Liang Leo

Jie Hui Nah

Hui Ying Ang

Chuen Neng Lee

Jimmy Kim Fatt Hon

Affiliations

Soon will be listed here.

Abstract

Background: Intervention for tricuspid regurgitation (TR) tends to happen concurrently with and is addressed during mitral valve surgery. Isolated TR interventions, however, are not unusual and are becoming more common. The purpose of this study was to provide a general overview of the transcatheter tricuspid valve implantation (TTVI) devices, taking into account the several design variations, and to unify the implantation technique, existing clinical results, and potential future directions for TR replacement therapy.

Methods: The major databases, namely Pubmed via Medline, Embase, and Cochrane library, were systematically searched from the date of conception until 10 February 2023, in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) standards.

Results: Eleven studies were isolated from a total cohort of 5842 publications. All the transcatheter tricuspid prostheses were circular in design yet categorized into annular tricuspid valve implantation (ATVI) and caval valve implantation (CAVI) groups. Bleeding (25.2%), severe access site and vascular issues requiring intervention (5.8%), device migration or embolization (3.6%), and paravalvular leak (38%) are among the early TTVI-related complications that have been observed. The CAVI group experienced 3 of 28 bleeding cases and 2 of 4 device migration cases.

Conclusions: Following the intervention with a transcatheter tricuspid prosthesis, this review discovered an early favorable outcome and a general improvement in heart failure symptoms. However, there was a lot of variation in their design, implantation technique, and early clinical outcomes. Understanding the design variations, difficulty of implantation and learning from this review's key findings could help with the future development of catheter-based tricuspid valves.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022312142.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

Aoi S, Wiley J, Ho E, Goldberg Y, Chau M, Latib A . Transcatheter tricuspid valve implantation with the Cardiovalve system. Future Cardiol. 2021; 17(6):963-969. DOI: 10.2217/fca-2020-0181. View

Lauten A, Figulla H, Unbehaun A, Fam N, Schofer J, Doenst T . Interventional Treatment of Severe Tricuspid Regurgitation: Early Clinical Experience in a Multicenter, Observational, First-in-Man Study. Circ Cardiovasc Interv. 2018; 11(2):e006061. DOI: 10.1161/CIRCINTERVENTIONS.117.006061. View

Lu F, Ma Y, An Z, Cai C, Li B, Song Z . First-in-Man Experience of Transcatheter Tricuspid Valve Replacement With LuX-Valve in High-Risk Tricuspid Regurgitation Patients. JACC Cardiovasc Interv. 2020; 13(13):1614-1616. DOI: 10.1016/j.jcin.2020.03.026. View

Boudjemline Y, Agnoletti G, Bonnet D, Behr L, Borenstein N, Sidi D . Steps toward the percutaneous replacement of atrioventricular valves an experimental study. J Am Coll Cardiol. 2005; 46(2):360-5. DOI: 10.1016/j.jacc.2005.01.063. View

Lauten A, Figulla H, Willich C, Laube A, Rademacher W, Schubert H . Percutaneous caval stent valve implantation: investigation of an interventional approach for treatment of tricuspid regurgitation. Eur Heart J. 2009; 31(10):1274-81. DOI: 10.1093/eurheartj/ehp474. View

Lauten A, Ferrari M, Hekmat K, Pfeifer R, Dannberg G, Ragoschke-Schumm A . Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation. Eur Heart J. 2011; 32(10):1207-13. PMC: 3094550. DOI: 10.1093/eurheartj/ehr028. View

Sharma N, Chouhan N, Bansal M, Chandra P, Singh A, Juneja R . Heterotopic caval valve implantation in severe tricuspid regurgitation. Ann Card Anaesth. 2021; 24(3):365-368. PMC: 8404582. DOI: 10.4103/aca.ACA_72_20. View

Lu F, Qiao F, Lv Y, An Z, Liu X, Cao P . A radial force-independent bioprosthesis for transcatheter tricuspid valve implantation in a preclinical model. Int J Cardiol. 2020; 319:120-126. DOI: 10.1016/j.ijcard.2020.06.070. View

10.

Alqahtani F, Berzingi C, Aljohani S, Hijazi M, Al-Hallak A, Alkhouli M . Contemporary Trends in the Use and Outcomes of Surgical Treatment of Tricuspid Regurgitation. J Am Heart Assoc. 2017; 6(12). PMC: 5779056. DOI: 10.1161/JAHA.117.007597. View

11.

Huczek Z, Mazurek M, Kochman J, Kralisz P, Jagielak D, Sacha J . Valve-in-valve transcatheter transfemoral mitral valve implantation (ViV-TMVI): Characteristics and early results from a nationwide registry. Kardiol Pol. 2023; 81(6):606-612. DOI: 10.33963/KP.a2023.0094. View

12.

Hahn R, Thomas J, Khalique O, Cavalcante J, Praz F, Zoghbi W . Imaging Assessment of Tricuspid Regurgitation Severity. JACC Cardiovasc Imaging. 2019; 12(3):469-490. DOI: 10.1016/j.jcmg.2018.07.033. View

13.

Nath J, Foster E, Heidenreich P . Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004; 43(3):405-9. DOI: 10.1016/j.jacc.2003.09.036. View

14.

Sun Z, Li H, Zhang Z, Li Y, Zhang L, Xie Y . Twelve-month outcomes of the LuX-Valve for transcatheter treatment of severe tricuspid regurgitation. EuroIntervention. 2021; 17(10):818-826. PMC: 9725022. DOI: 10.4244/EIJ-D-21-00095. View

15.

Rudzinski P, Kalinczuk L, Mintz G, Demkow M . Large field-of-view intravascular ultrasound offering tomographic perspective online for accurate sizing during transcatheter pulmonary valve replacement. Eur Heart J Cardiovasc Imaging. 2022; 23(7):e278. PMC: 9757892. DOI: 10.1093/ehjci/jeac075. View

16.

Riede F, Dahnert I . Implantation of a Melody valve in tricuspid position. Catheter Cardiovasc Interv. 2011; 80(3):474-6. DOI: 10.1002/ccd.23404. View

17.

Cahill T, Prothero A, Wilson J, Kennedy A, Brubert J, Masters M . Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation. Heart. 2021; 107(12):1003-1009. DOI: 10.1136/heartjnl-2020-318482. View

18.

Benedetto U, Melina G, Angeloni E, Refice S, Roscitano A, Comito C . Prophylactic tricuspid annuloplasty in patients with dilated tricuspid annulus undergoing mitral valve surgery. J Thorac Cardiovasc Surg. 2012; 143(3):632-8. DOI: 10.1016/j.jtcvs.2011.12.006. View

19.

Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos I, Cruz-Gonzalez I, Baz J, Pascual I . 6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study. JACC Cardiovasc Interv. 2022; 15(13):1366-1377. DOI: 10.1016/j.jcin.2022.05.022. View

20.

Russo G, Taramasso M, Pedicino D, Gennari M, Gavazzoni M, Pozzoli A . Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?. Eur J Heart Fail. 2021; 24(3):442-454. DOI: 10.1002/ejhf.2398. View